Elopag 20 mg is identified on this website as a medicine containing eltrombopag, an orally administered prescription medicine belonging to the thrombopoietin receptor agonist (TPO-RA) class. It is designed to help increase platelet production in the bone marrow in patients with certain medical conditions associated with low platelet counts.
Platelets are essential components of blood. They help maintain normal blood clotting by gathering at damaged blood vessels and supporting the formation of clots. When platelet levels become too low, the body may have difficulty controlling bleeding. This condition is known as thrombocytopenia.
Eltrombopag works by stimulating the thrombopoietin receptor, a biological target involved in the development and production of platelets. Through this activity, it can help increase platelet counts in appropriately selected patients.
This page explains the identity of Elopag, the pharmacological properties of eltrombopag, its therapeutic classification, recognised medical uses, clinical background, administration principles and important safety considerations.
What Is Elopag?
Elopag is the brand name specified for the product covered by this website. The listed product contains eltrombopag in a 20 mg strength.
Eltrombopag is a thrombopoietin receptor agonist. It acts on receptors expressed by certain blood-forming cells in the bone marrow. These cells are involved in the development of megakaryocytes, which are large cells responsible for producing platelets.
By activating the thrombopoietin receptor pathway, eltrombopag can stimulate the production of platelets.
Unlike medicines that primarily suppress immune activity or prevent platelet destruction, eltrombopag works mainly by promoting platelet production.
Elopag Product Information
| Product characteristic | Details |
|---|---|
| Brand name | Elopag |
| Generic name | Eltrombopag |
| Listed strength | 20 mg |
| Drug class | Thrombopoietin receptor agonist |
| Therapeutic category | Haematological medicine |
| Administration route | Oral |
| Dosage form | Tablet, subject to product packaging verification |
| Main therapeutic role | Increasing platelet production |
| Manufacturer | Not independently verified |
| Prescription status | Prescription medicine |
The 20 mg strength refers to the amount of eltrombopag identified for the listed product. It does not represent a universal treatment dose.
Different patients may require different daily doses depending on their diagnosis, age, platelet response, liver function and other medical factors.
What Is Eltrombopag?
Eltrombopag is a small-molecule medicine that stimulates the thrombopoietin receptor.
Thrombopoietin is a naturally occurring hormone that helps regulate platelet production. It plays an important role in the growth and maturation of megakaryocytes in the bone marrow.
When the body produces insufficient platelets, a patient may develop thrombocytopenia. This can happen because of increased platelet destruction, impaired production or a combination of biological processes.
Eltrombopag helps address reduced platelet production by stimulating the thrombopoietin receptor pathway.
It is not a general treatment for every cause of thrombocytopenia. Its use is limited to specific medical conditions and patient populations for which its benefits and risks have been evaluated.
Therapeutic Classification of Elopag
Elopag contains eltrombopag, which belongs to the following pharmacological category:
Thrombopoietin receptor agonists (TPO-RAs).
These medicines stimulate the thrombopoietin receptor and support platelet production.
Other platelet-directed medicines may work through different mechanisms. For example, some treatments reduce immune-mediated platelet destruction, while others affect platelet production through different molecular pathways.
Eltrombopag has a distinctive pharmacological mechanism because it stimulates the thrombopoietin receptor through a binding site different from the natural thrombopoietin binding site.
This mechanism helps explain its clinical role in selected blood disorders.
Medical Conditions Treated With Eltrombopag
Eltrombopag has recognised uses in selected conditions associated with low platelet counts and impaired blood-cell production. Approved indications depend on the applicable regulatory authority and product label.
1. Chronic Immune Thrombocytopenia
Immune thrombocytopenia, also called ITP, is an acquired immune disorder in which the body’s immune system mistakenly attacks platelets.
The immune system may produce antibodies that attach to platelets, leading to their destruction. In some patients, platelet production may also be impaired.
Symptoms may include:
- Unexplained bruising.
- Small red or purple skin spots.
- Nosebleeds.
- Bleeding gums.
- Heavy menstrual bleeding.
- Prolonged bleeding after minor injuries.
Eltrombopag may be prescribed for eligible patients with persistent or chronic ITP who have not responded adequately to certain previous treatments.
It stimulates platelet production and can help increase platelet numbers.
The treatment goal is generally to maintain a platelet count that reduces clinically important bleeding risk, rather than to achieve an unnecessarily high or completely normal platelet count.
2. Severe Aplastic Anemia
Aplastic anemia is a rare bone marrow disorder in which the marrow cannot produce enough blood cells.
Severe aplastic anemia can cause reductions in red blood cells, white blood cells and platelets.
Patients may experience fatigue, weakness, infections, bruising and bleeding.
Eltrombopag has an established treatment role in selected patients with severe aplastic anemia. Depending on the applicable prescribing indication, it may be used in combination with standard immunosuppressive treatment or in patients who have not responded adequately to previous immunosuppressive therapy.
Treatment decisions are made by specialist haematology teams.
3. Hepatitis C-Associated Thrombocytopenia
Chronic hepatitis C can be associated with low platelet counts, particularly in patients with advanced liver disease.
In certain interferon-based antiviral treatment settings, eltrombopag has been used to increase platelet levels sufficiently to support treatment.
This use is specific to the relevant approved treatment context. It should not be assumed that eltrombopag is routinely required for patients receiving modern interferon-free hepatitis C treatment.
The patient’s liver condition and potential thrombotic risks must be considered.
How Does Elopag Work in the Body?
Eltrombopag works through the thrombopoietin receptor, also called c-Mpl.
The receptor is involved in signalling processes that regulate the production of platelets.
After oral administration, eltrombopag is absorbed into the body and interacts with the thrombopoietin receptor.
This activates intracellular pathways involved in the proliferation and differentiation of platelet-producing cells.
The resulting activity can increase the development of megakaryocytes and promote platelet production.
Difference Between Platelet Production and Platelet Destruction
Platelet counts can become low for different reasons.
In some diseases, platelets are destroyed too rapidly by immune mechanisms. In other conditions, the bone marrow does not produce enough platelets.
Eltrombopag primarily supports platelet production.
It does not directly correct every cause of thrombocytopenia, and it does not eliminate the underlying immune or bone marrow disorder.
This distinction is important when healthcare professionals select treatment.
Development and Clinical Background
Eltrombopag was developed as an orally administered thrombopoietin receptor agonist.
Its clinical development focused on conditions in which increasing platelet production could provide a therapeutic benefit.
The medicine became an established treatment option in selected patients with chronic immune thrombocytopenia and severe aplastic anemia.
It has also been used in specific hepatitis C-associated thrombocytopenia treatment settings.
The development of eltrombopag provided an oral treatment approach for stimulating platelet production.
Clinical evidence and regulatory decisions have established specific indications, dosing requirements and safety precautions. These should always be interpreted according to the current prescribing information in the relevant country.
Elopag 20 mg and Available Strengths
This website focuses on Elopag 20 mg.
Eltrombopag is marketed in different strengths in international pharmaceutical markets. The available strengths and dosage forms depend on the manufacturer and jurisdiction.
The listed 20 mg strength should not be confused with the total daily dose prescribed to an individual patient.
Some treatment regimens require different strengths, dose adjustments or treatment schedules.
Patients should not combine tablets or change the dose without instructions from their healthcare professional.
Administration and Food Considerations
Eltrombopag is administered orally.
One of its most important administration considerations is the interaction with calcium and other polyvalent cations.
These minerals can bind eltrombopag in the digestive tract and reduce its absorption.
Conventional eltrombopag tablets are generally taken without food or with a meal containing no more than 50 mg of calcium.
They should generally be separated from calcium-rich foods, mineral supplements and antacids by at least 2 hours before or 4 hours after administration.
Examples include milk, dairy products, calcium supplements, iron supplements, magnesium-containing products, aluminium-containing antacids and zinc supplements.
Patients should follow the instructions provided with their actual prescribed product.
Important Precautions
Eltrombopag requires appropriate medical supervision.
Liver Function
Liver function tests are important before and during treatment because eltrombopag can cause liver-related adverse effects.
Thrombotic Complications
An excessive increase in platelet counts may contribute to the risk of blood clots.
Patients with liver disease or previous thrombotic events may require additional clinical consideration.
Blood Count Monitoring
Platelet counts and other blood parameters should be monitored according to the treatment indication.
Pregnancy and Breastfeeding
Patients who are pregnant, planning pregnancy or breastfeeding should discuss treatment risks and alternatives with their healthcare professional.
Drug Interactions
All prescription medicines, supplements, vitamins and mineral products should be disclosed before treatment begins.
Manufacturer and Brand Information
The product information supplied for this website identifies the brand as Elopag and the generic ingredient as eltrombopag.
However, the manufacturer of Elopag 20 mg has not been independently verified.
The original developer of eltrombopag, the manufacturer of a particular branded product, the brand owner and the distributor are not necessarily the same company.
The actual manufacturer and product details should be checked against the medicine packaging and official product documentation.
Frequently Asked Questions
What is Elopag 20 mg?
Elopag 20 mg is the listed brand product containing eltrombopag, a prescription medicine that stimulates platelet production in selected medical conditions.
What is the generic name of Elopag?
The generic medicine is eltrombopag.
Which drug class does Elopag belong to?
Elopag belongs to the thrombopoietin receptor agonist class.
How does eltrombopag increase platelet counts?
It stimulates the thrombopoietin receptor pathway and supports the development of platelet-producing cells in the bone marrow.
Is eltrombopag used for immune thrombocytopenia?
Yes. It is used in selected patients with persistent or chronic immune thrombocytopenia according to applicable prescribing information.
Is eltrombopag used for aplastic anemia?
Yes. It has recognised indications for selected patients with severe aplastic anemia.
Can eltrombopag be used for hepatitis C?
It has a recognised role in certain chronic hepatitis C-associated thrombocytopenia treatment settings, particularly involving interferon-based therapy.
Is Elopag a blood thinner?
No. Eltrombopag stimulates platelet production. It is not an anticoagulant or blood thinner.
Does eltrombopag require liver monitoring?
Yes. Liver function should be assessed before and during treatment as recommended by the prescribing information.
Can Elopag be taken with calcium supplements?
Calcium supplements can reduce eltrombopag absorption. Appropriate separation between the medicine and calcium-containing products is important.
Medical Disclaimer
This page provides general educational information about Elopag and eltrombopag. It does not replace official prescribing information, professional medical advice, diagnosis or individualized treatment recommendations.
Eltrombopag should only be used under appropriate medical supervision. Patients should not independently start treatment, change doses or discontinue prescribed medication.
The manufacturer, regulatory status and authenticity of the specific Elopag product should be verified using reliable product documentation.